Cargando…

Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)

BACKGROUND AND OBJECTIVES: This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuccitelli, Richard, LaTowsky, Brenda M., Lain, Edward, Munavalli, Girish, Loss, Lesley, Ross, E. Victor, Jauregui, Lauren, Knape, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291480/
https://www.ncbi.nlm.nih.gov/pubmed/34008877
http://dx.doi.org/10.1002/lsm.23423
_version_ 1784749144464687104
author Nuccitelli, Richard
LaTowsky, Brenda M.
Lain, Edward
Munavalli, Girish
Loss, Lesley
Ross, E. Victor
Jauregui, Lauren
Knape, William A.
author_facet Nuccitelli, Richard
LaTowsky, Brenda M.
Lain, Edward
Munavalli, Girish
Loss, Lesley
Ross, E. Victor
Jauregui, Lauren
Knape, William A.
author_sort Nuccitelli, Richard
collection PubMed
description BACKGROUND AND OBJECTIVES: This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non‐cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia. STUDY DESIGN/MATERIALS AND METHODS: Sixty‐two subjects were enrolled at a total of five sites. One hundred and ninety‐five study verrucae up to 10 mm wide were treated with NPS delivered by a console‐based handheld applicator (CellFX® System; Pulse Biosciences) and follow‐ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant. RESULTS: Overall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120‐day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures. CONCLUSIONS: NPS is a safe and effective procedure for removing non‐genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
format Online
Article
Text
id pubmed-9291480
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92914802022-07-20 Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae) Nuccitelli, Richard LaTowsky, Brenda M. Lain, Edward Munavalli, Girish Loss, Lesley Ross, E. Victor Jauregui, Lauren Knape, William A. Lasers Surg Med Clinical BACKGROUND AND OBJECTIVES: This study describes the effects of nano‐pulse stimulation (NPS) technology on the common verruca with the objectives of demonstrating efficacy and safety. NPS technology applies nanosecond pulses of non‐thermal electrical energy to induce highly localized regulated cell death in the cellular structures of the targeted zone with negligible effects on surrounding non‐cellular structures. Previous clinical studies applying NPS to common, benign skin lesions have demonstrated safety and efficacy in clearing seborrheic keratoses and sebaceous hyperplasia. STUDY DESIGN/MATERIALS AND METHODS: Sixty‐two subjects were enrolled at a total of five sites. One hundred and ninety‐five study verrucae up to 10 mm wide were treated with NPS delivered by a console‐based handheld applicator (CellFX® System; Pulse Biosciences) and follow‐ups occurred every 30 days with the option to retreat at 30, 60, and 90 days. There were 62 untreated controls and 46% of the treated verrucae were recalcitrant. RESULTS: Overall, 75.3% (70/93) of the common verrucae, 72.7% (8/11) of the flat verrucae, and 43.8% (14/32) of the plantar verrucae treated with NPS were completely clear by 60 days following the last treatment and did not recur within the 120‐day observation period. The majority (54%) of verrucae cleared with a single NPS procedure. The most common treatment site reactions were erythema (50.5%) and eschar formation (23.4%) on Day 30 and on Day 120 mild erythema was present in 14% of the cases and hyperpigmentation in 18.5%. No serious adverse events were reported. A particle counter was used during 11 NPS procedures on verrucae and no significant plume generation was detected during these procedures. CONCLUSIONS: NPS is a safe and effective procedure for removing non‐genital, cutaneous verrucae. Lasers Surg. Med. © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC. John Wiley and Sons Inc. 2021-05-19 2021-12 /pmc/articles/PMC9291480/ /pubmed/34008877 http://dx.doi.org/10.1002/lsm.23423 Text en © 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical
Nuccitelli, Richard
LaTowsky, Brenda M.
Lain, Edward
Munavalli, Girish
Loss, Lesley
Ross, E. Victor
Jauregui, Lauren
Knape, William A.
Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title_full Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title_fullStr Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title_full_unstemmed Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title_short Safety and Efficacy of Nano‐Pulse Stimulation Treatment of Non‐Genital, Cutaneous Warts (Verrucae)
title_sort safety and efficacy of nano‐pulse stimulation treatment of non‐genital, cutaneous warts (verrucae)
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291480/
https://www.ncbi.nlm.nih.gov/pubmed/34008877
http://dx.doi.org/10.1002/lsm.23423
work_keys_str_mv AT nuccitellirichard safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT latowskybrendam safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT lainedward safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT munavalligirish safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT losslesley safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT rossevictor safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT jaureguilauren safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae
AT knapewilliama safetyandefficacyofnanopulsestimulationtreatmentofnongenitalcutaneouswartsverrucae